Nice
With approximately 115 million outstanding shares at a price of 15 cents at the time of writing, the current market capitalization of GNLK is about $17 million. Interestingly, this matches the amount of paid-in-capital since the company’s inception, suggesting that investors still see as much value in GNLK now as they did 10 years ago.. GNLK shares traded in their highs between 75 cents and $1 in 2001 with the announcement of their SNP based screening patents, and more recently in 2008 they traded in the 50 cent range with the announcement of Genewize and a dramatic volume surge. Apart from the typical share price depression seen in nearly every stock due to the March 2009 market lows, GNLK has held the 10-15 cent range consistently. Together, this suggests that long-time investors continue to have faith in Genelink’s ability to become profitable. When new investors are attracted to GNLK, they see incredible potential in the company and drive up the share price considerably. Right now long investors are holding tight to their shares because the see exciting growth and a turn to profitability by Genelink right around the corner. When new investors look at the exciting implementation of the SNP technology in personalized care, solid foundation in science as demonstrated by their bolstered patent portfolio, proven marketing strategy as demonstrated by the dramatic growth of revenue after the Genewize launch, customer retention in the face of the The Great Recession, and finally Genelink’s increasing marketing power and revisions to increase their profit margin, GNLK share price should reach these new highs again. I am excited by the unique blend of the pharmacogenomics, nutragenetics, and dermagenetics an marketing strategy that Genelink offers, and as investor you should be also.
